Redeye provides its initial take on Surgical Science’s Q3 2025 report, which came in slightly below our top-line projection and missed our profitability estimates. Despite disappointing profitability, we believe this quarter was a reassuring move in the right direction after soft Q2 figures. Demand outlook for the seasonally strong fourth quarter appears to be solid, boding well for continued growth.
LÄS MER
